MedCity News January 19, 2026
Frank Vinluan

Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup financings announced during the annual J.P. Morgan Healthcare Conference this year.

The annual J.P. Morgan Healthcare Conference draws the attention of much of the healthcare industry, making the event a popular time to announce deals. Acquisition announcements were not as prolific this year. Outside of a Boston Scientific buyout, no major M&A deals were unveiled during the conference. Perhaps that’s because so many acquisitions were announced as 2024 drew to a close.

The sentiment of conferencegoers was optimistic, with some citing the IPO of Aktis Oncology as a possible sign of a reopening biotech IPO market. Financing activity is also picking up for startups,...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
Related Articles:
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat
Biotech investor Cormorant secures $150M for another SPAC deal
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety
Introducing the Sunday Times Tech 100: Life sciences part 1

Share Article